Trials / Completed
CompletedNCT00786812
Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the \[CAMN107A2109\] study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2008-11-06
- Last updated
- 2017-02-23
Locations
9 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00786812. Inclusion in this directory is not an endorsement.